Literature DB >> 33229294

Adherence with lipid screening guidelines in standard- and high-risk children and adolescents.

Justin H Berger1, Feiyan Chen2, Jennifer A Faerber2, Michael L O'Byrne3, Julie A Brothers4.   

Abstract

Because atherosclerosis begins in childhood, universal lipid screening is recommended with special attention to conditions predisposing to early atherosclerosis. Data about real-world penetration of these guidelines is not available.
METHODS: Retrospective cohort study using MarketScan® commercial and Medicaid insurance claims databases, a geographically representative sample of U.S. children. Subjects who passed through the 9- to 11-year window and had continuous insurance coverage between 1/1/2013 and 12/31/2016 were studied. Multivariable models were calculated, evaluating the association between other patient factors and the likelihood of screening. The primary hypothesis was that screening rates would be low, but that high-risk conditions would be associated with a higher likelihood of screening.
RESULTS: In total, 572,522 children (51% male, 33% black, 11% Hispanic, 51% Medicaid) were studied. The prevalence of high-risk conditions was 2.2%. In unadjusted and adjusted analyses, these subjects were more likely to be screened than standard-risk subjects (47% vs. 20%, OR: 3.7, 95% CI 3.5-3.8, P < .001). Within this group, the diagnosis-specific likelihood of screening varied (26-69%). Endocrinopathies (OR 5.4, 95% CI 5.2-5.7), solid organ transplants (OR 5.0, 95% CI 3.8-6.6), and metabolic disease (OR 3.9, 95% CI 3.1-5.0, all P < .001) were associated with the highest likelihood of undergoing screening.
CONCLUSIONS: Despite national recommendations, lipid screening was performed in a minority of children. Though subjects with high-risk conditions had a higher likelihood of screening, rates remained low. This study highlights the need for research and advocacy regarding obstacles to lipid screening of children in the United States.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33229294      PMCID: PMC7854880          DOI: 10.1016/j.ahj.2020.10.058

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  49 in total

1.  National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.

Authors: 
Journal:  Pediatrics       Date:  1992-03       Impact factor: 7.124

2.  Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of Obesity and Severe Obesity in US Children, 1999-2016. Pediatrics. 2018;141(3):e20173459.

Authors: 
Journal:  Pediatrics       Date:  2018-09       Impact factor: 7.124

3.  Physicians' Lack of Adherence to National Heart, Lung, and Blood Institute Guidelines for Pediatric Lipid Screening.

Authors:  Christopher W Valle; Helen J Binns; Maheen Quadri-Sheriff; Irwin Benuck; Angira Patel
Journal:  Clin Pediatr (Phila)       Date:  2015-03-26       Impact factor: 1.168

4.  Overly aggressive new guidelines for lipid screening in children: evidence of a broken process.

Authors:  Thomas B Newman; Mark J Pletcher; Stephen B Hulley
Journal:  Pediatrics       Date:  2012-07-23       Impact factor: 7.124

5.  Effect of Obesity and Underweight Status on Perioperative Outcomes of Congenital Heart Operations in Children, Adolescents, and Young Adults: An Analysis of Data From the Society of Thoracic Surgeons Database.

Authors:  Michael L O'Byrne; Sunghee Kim; Christoph P Hornik; Babatunde A Yerokun; Roland A Matsouaka; Jeffrey P Jacobs; Marshall L Jacobs; Richard A Jonas
Journal:  Circulation       Date:  2017-06-16       Impact factor: 29.690

6.  Implementation of lipid screening guidelines in children by primary pediatric providers.

Authors:  Damon B Dixon; Annabel P Kornblum; Lyn M Steffen; Xia Zhou; Julia Steinberger
Journal:  J Pediatr       Date:  2013-11-16       Impact factor: 4.406

Review 7.  Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics.

Authors:  Rae-Ellen W Kavey; Vivek Allada; Stephen R Daniels; Laura L Hayman; Brian W McCrindle; Jane W Newburger; Rulan S Parekh; Julia Steinberger
Journal:  Circulation       Date:  2006-11-27       Impact factor: 29.690

8.  Associations of arterial tissue lipids with coronary heart disease risk factors in young people.

Authors:  Gray T Malcom; C Alex McMahan; Henry C McGill; Edward E Herderick; Richard E Tracy; Dana A Troxclair; Jack P Strong
Journal:  Atherosclerosis       Date:  2008-07-12       Impact factor: 5.162

9.  Pediatric cholesterol screening practices in 9- to 11-year-olds in a large midwestern primary care setting.

Authors:  Carly Allen-Tice; Julia Steinberger; Kari Murdy; Heather Zierhut
Journal:  J Clin Lipidol       Date:  2020-01-31       Impact factor: 4.766

Review 10.  Epidemiology of chronic kidney disease in children.

Authors:  Jérôme Harambat; Karlijn J van Stralen; Jon Jin Kim; E Jane Tizard
Journal:  Pediatr Nephrol       Date:  2011-06-29       Impact factor: 3.714

View more
  6 in total

1.  Assessment of Underuse and Overuse of Screening Tests for Co-occurring Conditions Among Children With Obesity.

Authors:  Mona Sharifi; Alyson B Goodman; Kao-Ping Chua
Journal:  JAMA Netw Open       Date:  2022-07-01

2.  Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases.

Authors:  Michael L O'Byrne; Jennifer A Faerber; Hannah Katcoff; Jing Huang; Jonathan B Edelson; David M Finkelstein; Bethan A Lemley; Christopher M Janson; Catherine M Avitabile; Andrew C Glatz; David J Goldberg
Journal:  Am Heart J       Date:  2021-09-25       Impact factor: 4.749

3.  Adherence With Lipid Screening Guidelines in Children With Acquired and Congenital Heart Disease: An Observational Study Using Data From The MarketScan Commercial and Medicaid Databases.

Authors:  Justin H Berger; Jennifer A Faerber; Feiyan Chen; Kimberly Y Lin; Julie A Brothers; Michael L O'Byrne
Journal:  J Am Heart Assoc       Date:  2022-03-18       Impact factor: 6.106

4.  Impact of Device Miniaturization on Insertable Cardiac Monitor Use in the Pediatric Population: An Analysis of the MarketScan Commercial and Medicaid Databases.

Authors:  Dustin Nash; Hannah Katcoff; Jennifer Faerber; V Ramesh Iyer; Maully J Shah; Michael L O'Byrne; Christopher Janson
Journal:  J Am Heart Assoc       Date:  2022-08-05       Impact factor: 6.106

5.  SARS-CoV-2 acquisition and immune pathogenesis among school-aged learners in four diverse schools.

Authors:  Dan M Cooper; Michael Z Zulu; Allen Jankeel; Izabela Coimbra Ibraim; Jessica Ardo; Kirsten Kasper; Diana Stephens; Andria Meyer; Annamarie Stehli; Curt Condon; Mary E Londoño; Casey M Schreiber; Nanette V Lopez; Ricky L Camplain; Michael Weiss; Charles Golden; Shlomit Radom-Aizik; Bernadette Boden-Albala; Clayton Chau; Ilhem Messaoudi; Erlinda R Ulloa
Journal:  Pediatr Res       Date:  2021-07-24       Impact factor: 3.756

6.  Barriers in utilizing lipid-lowering agents in non-institutionalized population in the U.S.: Application of a theoretical framework.

Authors:  Abdullah A Alfaifi; Leanne Lai; Abdullah U Althemery
Journal:  PLoS One       Date:  2021-08-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.